In vitro activity of menogaril and N-demethylmenogaril in a human tumor cloning assay

Dodion, Pierre; Sanders, Charlotte; Rombaut, W.; Rozencweig, Marcel; Kitt, Michael M.; Kenis, Yvon; Klastersky, Jean

doi:10.1016/0277-5379(86)90387-1

Cited by 2 publications

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Menogaril (7-con-0-methylnogarol, menogarol, NSC-269148) is a semisynthetic anthracycline antibiotic derived from nogalamycin with significant activity against a variety of murine tumors [1,2] and human tumors in vitro [3]. The drug differs from the parent compound by the removal of the carbomethoxy group at C-10 and the replacement of the neutral sugar at C-7 by methoxyl in a con configuration.…”

Section: Introductionmentioning

confidence: 99%

Phase II trial of menogaril in advanced colorectal cancer

Holdener¹,

Huinink²,

Decoster³

et al. 1988

Invest New Drugs

View full text Add to dashboard Cite

Menogaril, a new semisynthetic anthracycline antibiotic, was administered to 35 patients with advanced colorectal cancer. The drug was infused over 2 hr at a dose of 160 mg/sqm or 200 mg/sqm repeated every 4 weeks. Twenty-seven patients were evaluable for response and no objective responses were achieved. Myelosuppression, only leukopenia, was usually of mild-moderate degree and occurred in 63% of the patients. Twenty-seven percent of the patients experienced severe leukopenia. Local erythema and phlebitis were frequently observed and were severe in 13% of the patients. Nausea/vomiting (66%) and alopecia (50%) were. of mild-moderate degree. This study suggests that menogaril at these doses and schedule had no activity in advanced colorectal cancer.

show abstract

Section: Introductionmentioning

confidence: 99%